Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece.

Published

Journal Article

The in vitro activity of plazomicin was evaluated against 300 multidrug resistant (MDR) (carbapenemase and/or ESBL-producing) isolates from four hospitals in Athens, an area where carbapenemase-producing organisms are endemic. Most of the isolates were also resistant to the legacy aminoglycosides with the MIC₅₀/MIC₉₀ to tobramycin, amikacin and gentamicin being 32/>32, 32/>32 and 4/>8 μg/ml, respectively. ACHN-490 retained activity (MICs ≤ 4 μg/ml) against all isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. tested with MIC₅₀ and MIC₉₀ of 1 and 2 μg/ml, respectively, irrespective of their MDR phenotype and it represents a promising alternative for the treatment of the most problematic Gram-negative pathogens.

Full Text

Cited Authors

  • Galani, I; Souli, M; Daikos, GL; Chrysouli, Z; Poulakou, G; Psichogiou, M; Panagea, T; Argyropoulou, A; Stefanou, I; Plakias, G; Giamarellou, H; Petrikkos, G

Published Date

  • August 2012

Published In

Volume / Issue

  • 24 / 4

Start / End Page

  • 191 - 194

PubMed ID

  • 23040681

Pubmed Central ID

  • 23040681

Electronic International Standard Serial Number (EISSN)

  • 1973-9478

International Standard Serial Number (ISSN)

  • 1120-009X

Digital Object Identifier (DOI)

  • 10.1179/1973947812Y.0000000015

Language

  • eng